Press Releases | Y-mAbs Therapeutics, Inc.

Year

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

Reported Total DANYELZA Net Product Revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increase Continued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico ; DANYELZA now approved in Hong Kong Part A of

Aug 12, 2024

Y-mAbs to Participate in Upcoming Investor Conferences in August

NEW YORK , Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of

Aug 07, 2024

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

NEW YORK , Aug. 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of

Aug 05, 2024

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

NEW YORK , July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of

Jul 01, 2024

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

NEW YORK , June 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of

Jun 07, 2024

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

NEW YORK , June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of

Jun 05, 2024

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

NEW YORK , June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of

Jun 01, 2024

Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting

Jun 01, 2024

Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments

Reported U.S. DANYELZA® net product revenues of $ 18.6 million for the first quarter of 2024, representing a YoY increase of 11% Reported Worldwide DANYELZA net product revenues of $19.4 million for the first quarter of 2024, representing a 4% YoY decrease due to international volumes Cash and cash

May 07, 2024

Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024

The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ET NEW YORK , April 26, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended March 31,

Apr 26, 2024

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 16